Kangpu Completes Patient Enrollment for Phase IIa Clinical Trial of KPG-818 in SLE in the US
Kangpu Biopharmaceuticals a clinical-stage company based in Shanghai, China, announced today that the Company has completed patient enrollment for the Phase IIa clinical trial of KPG-818 aimed at the treatment of systemic lupus erythematosus (SLE) in the US. The statement(s) made in this press release describing Kangpu's predictions, expectations and objectives may be forward-looking statements within the meaning of all applicable laws and regulations. These statements and expectations envisaged by the management are only estimates. Actual results may differ materially from such expectations due to risks, uncertainties and other factors, including, but not limited to, changes in regulatory and/or economic conditions, uncertain outcomes in the clinical studies, exposure to market risks, and other external and internal factors, which are beyond the control of Kangpu.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
